Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacovigilance

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...

Pharmacokinetic Models: Comparison and Selection Criterion

Pharmacokinetic Models: Comparison and Selection Criterion

Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.

Bioequivalence Data: Statistical Interpretation

Bioequivalence Data: Statistical Interpretation

The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...

Bioequivalence of Drugs: Drugs with Multiple Indications

Bioequivalence of Drugs: Drugs with Multiple Indications

The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...

Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches

Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches

Drug disposition in the body is a complex process and can be studied using two major approaches: the model and the model-independent approaches.
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...

Measurement of Bioavailability: Pharmacodynamic Methods

Measurement of Bioavailability: Pharmacodynamic Methods

Pharmacodynamic methods provide insights into a drug's effects on physiological processes over time and play a crucial role in understanding bioavailability and therapeutic efficacy. These methods can be broadly classified into acute pharmacological and therapeutic response approaches, each with distinct mechanisms and applications.The acute pharmacological response method directly correlates a drug's physiological effects, such as ECG or pupil diameter changes, to its time course in the body.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Pre-existing Comorbidities as Potential Risk Modifiers for New-Onset Myocarditis and Pericarditis following mRNA COVID-19 Vaccination in Males Aged 18-30 in the United States: A Disproportionality Analysis using VAERS Spontaneous Reporting Data.

Drugs - real world outcomes·2026

Same author

Serious respiratory distress associated with bosentan administration in chronic thromboembolic pulmonary hypertension: A case report.

Therapie·2026

Same author

Medication errors in malaria management in children: insights from pharmacovigilance data in the Democratic Republic of Congo.

BMC pharmacology & toxicology·2025

Same author

ASOS, a national monitoring study to assess narcotic prescriptions and indications in France since 2001.

Therapie·2024

Same author

From regional signal to alert in addictovigilance.

Therapie·2024

Same author

Use of the French National Health Data System (SNDS) in pharmacoepidemiology: A systematic review in its maturation phase.

Therapie·2024

Search research articles

Related Experiment Video

Updated: Jun 24, 2026

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

Bayesian pharmacovigilance signal detection methods revisited in a multiple comparison setting.

Ismaïl Ahmed¹, Françoise Haramburu, Annie Fourrier-Réglat

¹Inserm, U780, 16 Avenue Paul Vaillant Couturier, Villejuif F-94807, France. ismail.ahmed@inserm.fr

Statistics in Medicine

|April 11, 2009

Summary

This study introduces a new signal ranking method for pharmacovigilance databases, improving adverse drug reaction detection. The Bayesian approach offers better evaluation of drug safety signals compared to existing methods.

More Related Videos

Diagonal Method to Measure Synergy Among Any Number of Drugs

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

A Protocol for Using Gene Set Enrichment Analysis to Identify the Appropriate Animal Model for Translational Research

A Protocol for Using Gene Set Enrichment Analysis to Identify the Appropriate Animal Model for Translational Research

Published on: August 16, 2017

Related Experiment Videos

Last Updated: Jun 24, 2026

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

Diagonal Method to Measure Synergy Among Any Number of Drugs

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

A Protocol for Using Gene Set Enrichment Analysis to Identify the Appropriate Animal Model for Translational Research

A Protocol for Using Gene Set Enrichment Analysis to Identify the Appropriate Animal Model for Translational Research

Published on: August 16, 2017

Area of Science:

Pharmacovigilance and Drug Safety
Biostatistics and Computational Methods
Regulatory Science

Background:

Spontaneous reporting systems are crucial for early detection of adverse drug reactions.
Current signal detection methods lack auto-evaluation of signal quality, leading to arbitrary alert thresholds.
Existing methods for analyzing large spontaneous reporting databases (SRD) have limitations in signal assessment.

Purpose of the Study:

To develop and evaluate a novel signal ranking procedure for pharmacovigilance SRDs.
To integrate Bayesian decision theory with existing models like Gamma Poisson Shrinkage (GPS) and Bayesian Confidence Propagation Neural Network (BCPNN).
To enable non-mixture modeling for deriving Bayesian estimators of key performance metrics like false discovery rate (FDR).

Main Methods:

Revisiting the Gamma Poisson Shrinkage (GPS) and Bayesian Confidence Propagation Neural Network (BCPNN) models within a Bayesian general decision framework.
Proposing a new signal ranking procedure based on the posterior probability of the null hypothesis.
Developing an original data generation process suitable for SRD features and applying it to the French SRD for a large-scale simulation study.

Main Results:

The proposed ranking procedure demonstrated improved performance regarding the false discovery rate (FDR) compared to current methods for the GPS model.
Identical performances across four operating characteristics were observed for the proposed procedure using both BCPNN and GPS models.
The GPS model provided better estimates for performance metrics when using the proposed ranking procedure.

Conclusions:

The developed Bayesian signal ranking procedure enhances the evaluation of drug safety signals in spontaneous reporting databases.
The method provides more reliable Bayesian estimators for performance metrics, improving the assessment of signal detection.
Application to French pharmacovigilance data validates the proposed procedure's utility and performance.